Recursion Pharmaceuticals Stock Today
| RXRX Stock | USD 3.49 0.09 2.51% |
PerformanceWeakest
| Odds Of DistressSmall
|
Recursion Pharmaceuticals is trading at 3.49 as of the 17th of February 2026; that is 2.51 percent decrease since the beginning of the trading day. The stock's open price was 3.58. Recursion Pharmaceuticals has about a 27 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of November 2025 and ending today, the 17th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of April 2021 | Category Healthcare | Classification Health Care |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company has 514.19 M outstanding shares of which 165.55 M shares are at this time shorted by private and institutional investors with about 8.17 trading days to cover. More on Recursion Pharmaceuticals
Moving against Recursion Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Recursion Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman CoFounder | Christopher Gibson | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Nasdaq CTA Artificial, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRecursion Pharmaceuticals utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Recursion Pharmaceuticals' leverage profile, showing how much of Recursion Pharmaceuticals' resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recursion Pharmaceuticals (RXRX) is traded on NASDAQ Exchange in USA and employs 800 people. Recursion Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.82 B. Recursion Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 514.19 M outstanding shares of which 165.55 M shares are at this time shorted by private and institutional investors with about 8.17 trading days to cover.
Recursion Pharmaceuticals currently holds about 515.44 M in cash with (359.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98.
Check Recursion Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationRecursion Pharmaceuticals owns a total of 514.19 Million outstanding shares. Over half of Recursion Pharmaceuticals' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Recursion Ownership Details
Recursion Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2025-06-30 | 7.8 M | |
| Nvidia Corp | 2025-06-30 | 7.7 M | |
| Data Collective Iv Gp, Llc | 2025-06-30 | 5.9 M | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 5.7 M | |
| Fmr Inc | 2025-06-30 | 5.6 M | |
| Ubs Group Ag | 2025-06-30 | 4.6 M | |
| Ubs Asset Mgmt Americas Inc | 2025-06-30 | 4.6 M | |
| Dcvc Opportunity Fund Ii Gp, Llc | 2025-06-30 | 4 M | |
| Exor Investments (uk) Llp | 2025-06-30 | 3.7 M | |
| Vanguard Group Inc | 2025-06-30 | 36.1 M | |
| Ark Investment Management Llc | 2025-06-30 | 33 M |
Recursion Pharmaceuticals Historical Income Statement
Recursion Stock Against Markets
Recursion Pharmaceuticals Corporate Management
| Najat Khan | Chief Officer | Profile | |
| Kevin Leggat | Vice Accounting | Profile | |
| Janelle Gordon | Vice Operations | Profile | |
| Shafique MD | Interim Officer | Profile | |
| Lina Nilsson | Senior Platform | Profile |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.